Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

Bausch Health (NYSE:BHC) and Solta Medical launched the Clear + Brilliant Touch laser in Canada following Health Canada approval on May 20, 2025.

Rhea-AI Summary

Bausch Health (NYSE:BHC) and Solta Medical launched the Clear + Brilliant Touch laser in Canada following Health Canada approval on May 20, 2025. The dual-wavelength fractional laser expands Canadian access to customizable, low‑downtime skin resurfacing for multiple skin types and ages.

The System uses two handpieces (1440 nm and 1927 nm) with specific indications for wrinkles, dyschromia, pigmentation, texture and pore size, and is positioned as a year‑round, easy‑to‑use aesthetic option for physicians.

Positive

• Health Canada approval secured on May 20, 2025
• Launch expands Canadian market access for Solta aesthetics portfolio
• Dual-wavelength design (1440 nm and 1927 nm) enables targeted indications
• Indicated for skin resurfacing and soft‑tissue coagulation across multiple concerns
• Suitable for all skin types with minimal downtime and customizable treatments

Negative

• None.

Argus Feb 23 session

-2.45% close to close Open Argus

Details

News Market Reaction – BHC

On Feb 23, the day this news came out, BHC closed 2.45% below the previous close.

Data tracked by StockTitan Argus for the Feb 23 session.

Market Context

This announcement highlights further commercialization of Bausch Health’s Solta aesthetics portfolio...

Analysis

This announcement highlights further commercialization of Bausch Health’s Solta aesthetics portfolio, extending the Clear + Brilliant Touch laser into Canada after earlier U.S. rollout. It reinforces the company’s focus on non‑invasive skin rejuvenation within a diversified business that also recently reported full-year revenue of $10.27 billion. Investors may watch how adoption in Canada contributes to Solta’s growth alongside ongoing clinical, regulatory, and leverage developments detailed in recent filings and earnings updates.

Key Figures

Health Canada approval date: May 20, 2025 1440 nm wavelength: 1440 nm 1927 nm wavelength: 1927 nm

Health Canada approval date

May 20, 2025

Clear + Brilliant Touch laser approval in Canada

1440 nm wavelength

1440 nm

Clear + Brilliant Touch fractional laser handpiece

1927 nm wavelength

1927 nm

Clear + Brilliant Touch fractional laser handpiece

Historical Context

5 past events · Latest: Feb 19

5 events

1. Feb 19

   Product milestone

   24h Move

   -2.0%

   ARESTIN 25th anniversary and expanded presence in North America.

2. Feb 18

   Earnings results

   24h Move

   +3.3%

   Q4 and full-year 2025 revenue and EBITDA growth with guidance.

3. Feb 17

   Conference participation

   24h Move

   +0.0%

   Planned appearance at J.P. Morgan Global Leveraged Finance Conference.

4. Feb 11

   CSR / scholarships

   24h Move

   -1.3%

   Launch of 2026 Salix Gastrointestinal Health Scholars Program.

5. Jan 23

   Clinical trial update

   24h Move

   -10.1%

   Phase 3 RED-C program failed to meet primary endpoint.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dual-wavelength, fractional laser, coagulation of soft tissue, dyschromia, +1 more

5 terms

dual-wavelength technical

"one of the most advanced dual-wavelength laser technologies on the market"

Dual-wavelength describes a device or technique that uses two different colors (wavelengths) of light to measure, image, or treat tissue or materials either at the same time or in sequence. Using two wavelengths can improve accuracy, separate overlapping signals, or combine complementary effects, which matters to investors because it can make a product more effective, easier to get approved, and more competitive—like a two-tool gadget that handles more jobs than a single tool.

fractional laser medical

"The system includes two distinct fractional laser handpieces, each with its own indication"

A fractional laser is a medical device that delivers focused beams of light to create tiny, controlled wounds in columns across the skin while leaving surrounding tissue untouched — like punching a pattern of small holes in a fabric so the rest holds together. It is used to treat wrinkles, scars and pigmentation, and matters to investors because device sales, treatment demand, safety profile and regulatory clearance directly affect revenue, clinic adoption and liability risk for companies in the dermatology and medical aesthetics market.

coagulation of soft tissue medical

"indicated for use in dermatological procedures requiring the coagulation of soft tissue"

Coagulation of soft tissue describes the process of causing proteins and fluid in muscles, fat or connective tissue to thicken and form a stable mass, often to stop bleeding or seal tissue during a medical procedure. For investors, it signals a therapy or device function — like a surgical tool or treatment — that controls bleeding and reduces healing complications, which can affect clinical outcomes, regulatory approval prospects and market demand much like a reliable leak-sealing tool matters in construction.

dyschromia medical

"Indicated for the treatment of and improvement in the appearance of:WrinklesDyschromia"

Dyschromia is a medical term for patches of skin that become darker or lighter than surrounding skin due to changes in pigment or blood supply. For investors, dyschromia matters because it can appear as a reported side effect in drug or cosmetic studies, prompt regulatory review, or drive demand for corrective products — like rust on a car signaling repairs, visible skin changes can affect safety perceptions, approvals and sales prospects.

skin resurfacing medical

"procedures requiring the coagulation of soft tissue and general skin resurfacing"

A set of dermatology procedures that remove or renew the outer layers of skin to reduce scars, wrinkles, discoloration, or uneven texture; methods include lasers, chemical peels, or mechanical abrasion. Think of it like sanding and refinishing the surface of furniture to reveal smoother, fresher material underneath. For investors, trends in demand, treatment costs, device sales, and regulation affect revenue potential and risk for companies in medical aesthetics and dermatology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant^® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wavelength laser technologies on the market, expanding access to customizable treatments that align with the country's growing preference for effective yet approachable skin rejuvenation options.

"The Solta business continues to expand its global presence through its diverse and well-established portfolio that supports the growing demand for high-quality aesthetics solutions," said Thomas J. Appio, Chief Executive Officer, Bausch Health. "Canada is an important part of that growth, reflecting strong and sustained interest in the aesthetic market across the country."

Building on the successful U.S. launch of the Clear + Brilliant Touch System in 2021, the device's innovative design allows for seamless use of two handpieces with unique wavelengths to deliver comprehensive treatments that help reveal smoother, more radiant, youthful-looking skin. The System is suitable for all skin types, a wide range of  ages, can be used year-round (at the discretion of the treating physician) and is recognized for its ease of use, minimal downtime and gentle and effective results.

"Expanding the availability of the Clear + Brilliant Touch System into Canada marks a significant step forward for Solta Medical and its commitment to global expansion of our innovative portfolio of products in skin health," said Jiny Kim, Senior Vice President, Solta Medical, Bausch Health. "This launch reinforces Solta's leadership in supporting both providers and patients with technology that delivers safe, effective and customizable results."

Clear + Brilliant^® Touch Laser Indications (Canada)
The Clear + Brilliant^® Touch System is indicated for use in dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing. The system includes two distinct fractional laser handpieces, each with its own indication:

1440 nm Handpiece

• Indicated for the treatment of and improvement in the appearance of:
• Wrinkles
• Dyschromia
• Pigmentation
• Skin texture
• Pore size

1927 nm Handpiece

• Indicated for the treatment of and improvement in the appearance of:
• Wrinkles
• Dyschromia
• Pigmentation
• Skin texture
• Enhancement of skin permeability
• Pore Size

About the Clear + Brilliant^® Touch Laser
Solta Medical's Clear + Brilliant^® Touch laser is now available in Canada, joining the Clear + Brilliant^® portfolio. Supported by robust, evidence‑based data, including more than 15 clinical studies, the Clear + Brilliant^® laser platform uses fractional laser technology to create structural and functional changes in the skin. In Canada, these treatments help address early signs of aging, maintain youthful‑looking skin, and improve the skin's overall appearance.

Since 2011, the Clear + Brilliant^® platform has helped define the laser-treatment landscape across global markets.

For more information and Important Safety Information about the use of the Clear + Brilliant^® Touch laser, visit ca.clearandbrilliant.com/hcp.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our aesthetic business, Solta Medical, is a global leader in the aesthetics market, whose vision is to develop and support trusted aesthetic brands that provide value to our customers and patients. More information about Solta Medical can be found at www.solta.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

BHC-PRODUCTS
Investor Contact:	Media Contact:
Garen Sarafian	Katie Savastano
ir@bauschhealth.com	corporate.communications@bauschhealth.com
(877) 281-6642 (toll free)	(908) 569-3692

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-healths-aesthetics-business-solta-medical-announces-the-launch-of-clear--brilliant-touch-laser-in-canada-302694162.html

SOURCE Bausch Health Companies Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did BHC and Solta Medical receive Health Canada approval for Clear + Brilliant Touch?

They received Health Canada approval on May 20, 2025, enabling Canadian commercial availability. According to the company, this regulatory clearance permits physicians to offer the dual‑wavelength Clear + Brilliant Touch System across Canada.

What are the clinical indications for the Clear + Brilliant Touch laser in Canada (BHC)?

The System is indicated for general skin resurfacing and soft tissue coagulation. According to the company, the 1440 nm and 1927 nm handpieces target wrinkles, dyschromia, pigmentation, texture and pore size.

How might the Clear + Brilliant Touch launch affect Solta Medical's presence in Canada (BHC)?

The launch broadens Solta's Canadian footprint and provider access to its portfolio. According to the company, expanding availability supports growth in non‑invasive aesthetic demand and provider adoption of dual‑wavelength technology.

What technical features distinguish the Clear + Brilliant Touch System sold by BHC in Canada?

The System features two fractional laser handpieces with distinct wavelengths (1440 nm and 1927 nm). According to the company, this enables complementary treatment options for multiple skin concerns and customizable protocols.

Is the Clear + Brilliant Touch System suitable for year‑round treatment in Canada (BHC)?

Yes; it can be used year‑round at the treating physician's discretion. According to the company, the device is noted for ease of use, minimal downtime and suitability across a wide range of ages and skin types.